Publication | Closed Access

Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: Findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS

ThrombosisVenous ThrombosisCardiovascular DiseaseIschemic StrokeMedicineNew ThrombolyticClinical EpidemiologyHematologyFibrinolysisCoagulopathyNeurologyAntithrombotic CombinationsPublic HealthPlatelet AntagonistStrokeAnticoagulantAtherosclerosisAssent-3 Plus